CliffBio
small molecule

ELCYS

CYSTEINE HYDROCHLORIDE

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry
CompanyExela Pharma Sciences Llc →See this company's full patent-cliff portfolio

Drug detail

Brand nameELCYS
Active ingredientCYSTEINE HYDROCHLORIDE
Strength500MG/10ML (50MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2019
Marketing statusRX

Listed patents

PatentExpiresType
11510942January 2039product
11969439January 2039use U-2752
10478453January 2039product
10583155January 2039product
10653719January 2039product
10918662January 2039product
10905713January 2039product
10905714January 2039product
11684636January 2039product
10933089January 2039product
11826383January 2039product
11679125January 2039product
11648262January 2039product
10912795January 2039product
11642370January 2039product
11510941January 2039product

More from Exela Pharma Sciences Llc

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ELCYS patent cliff — loss of exclusivity January 2039 | CliffBio